Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PLAU | P00749 | 2/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | PLAT | P00750 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10160403 | 0.88 | ROCK2 (0.65) | ROCK2CYP3A4CYP2C19PLAUKLKB1 | |
| SCHEMBL15876355 | 0.85 | ROCK2 (0.72) | ROCK2CYP3A4CYP2C19PLAUMEN1 | |
| SCHEMBL15888443 | 0.83 | ROCK2 (0.61) | ROCK2PLAULOXL2KLKB1PLG | |
| SCHEMBL307838 | 0.82 | ROCK2 (0.81) | ROCK2CYP3A4CYP2C19PLAU | |
| SCHEMBL15653197 | 0.82 | PTGS1 (0.59) | ROCK2PLAULOXL2KLKB1PLG | |
| SCHEMBL15888437 | 0.82 | ROCK2 (0.70) | ROCK2CYP3A4CYP2C19MEN1FFAR1 | |
| SCHEMBL10160238 | 0.82 | ROCK2 (0.74) | ROCK2CYP3A4CYP2C19MEN1KMT2A | |
| SCHEMBL19964495 | 0.82 | LOXL2 (0.62) | ROCK2PLAULOXL2MEN1KMT2A | |
| SCHEMBL319411 | 0.81 | ROCK2 (0.82) | ROCK2CYP3A4CYP2C19 | |
| SCHEMBL307307 | 0.81 | ROCK2 (0.86) | ROCK2CYP3A4CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | claimed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | ROCK2 4/4885CYP3A4 2048/4885CYP2C19 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.